Clinical trials: CtDNA
Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Pancreatectomy, Chemotherapy Effect
- Trial name
- NORPACT-3 (NCT06944587)
- Testing
- Chemotherapy, Radiology, Pancreatectomy
- Where
- 5 sites in Norway
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Resectable Pancreatic Cancer
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases.
- Trial name
- ICAPAC (NCT03435536)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 35 people
- Sponsor
- University Hospital, Toulouse
Non-hodgkin Lymphoma, B Cell
LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma
Prevention and treatment of CNS relapse remains a great unmet clinical need in the management of aggressive B-NHL. Hence, investigating novel diagnostic tests is of paramount importance to improve risk-stratification of lymphoma…
- Trial name
- SAKK 38/23 (NCT06090162)
- Testing
- ctDNA detection
- Where
- 14 sites in Switzerland
- Volunteers
- 64 people
- Sponsor
- Swiss Cancer Institute
Non-small Cell Lung Cancer
ctDNA as a Biomarker for Treatment in Advanced NSCLC
The dynamic monitoring of circulating tumor DNA aims to evaluate the response and progression-free survival of short-course chemotherapy (2 cycles) combined with immunotherapy in patients with locally advanced unresectable or…
- Trial name
- NCT05486988
- Testing
- Immunotherapy, Chemotherapeutic Agent, Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fuzhou General Hospital
ctDNA, Colorectal Cancer
Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer
The patient (T4N0 or low-risk stage III) will be randomly assigned to either the control group (FOLFOX/CAPOX for 3 months) or the intervention group (FOLFOX/CAPOX for 6 months or FOLFOX/CAPOX for 3 months followed by…
- Conditions
- ctDNA, Colorectal Cancer, Chemotherapy
- Trial name
- CLEAR-03 (NCT07562503)
- Testing
- CAPEOX regimen
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Fudan University
Esophageal Adenocarcinoma, Gastric Cancer
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment.
- Conditions
- Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CIT-SEQ (NCT07660627)
- Testing
- NGS sequencing of mutations selected based on sequencing of primary tumors
- Where
- Czechia
- Volunteers
- 34 people
- Sponsor
- Masaryk Memorial Cancer Institute
Primary Central Nervous System Lymphoma (PCNSL)
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence).
- Trial name
- NCT04401774
- Testing
- Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer, Circulating Tumor DNA
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.
- Conditions
- Metastatic Breast Cancer, Circulating Tumor DNA, Gene Abnormality
- Trial name
- ACTDNAGLT (NCT05427617)
- Testing
- Control group, Case group
- Volunteers
- 223 people
- Sponsor
- Hunan Cancer Hospital
Melanoma, Melanoma Stage III
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less…
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Trial name
- NCT06199713
- Testing
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Solid Tumors, Identified by NGS, PCR or IHC
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
The purpose of this study is to test the safety of the study drug, pembrolizumab, and to find out how well it works to prevent cancer from coming back in people who have had a solid tumor surgically removed, but still have tumor…
- Trial name
- NCT03832569
- Testing
- Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon or Upper Rectum Adenocarcinoma
Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer
Phase III multicentric, open-label, randomized study The main objective is to assess the efficacy on time to disease recurrence (TTR) of treating minimal residual disease diagnosed by the presence of ctDNA after full treatment…
- Trial name
- CIRCULATE PAC (NCT06197425)
- Testing
- "FOLFIRI" cures, Trifluridine cures, BIOLOGICAL ASSESSMENT
- Where
- France
- Volunteers
- 1,660 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Rectal Neoplasms, Neoadjuvant Therapy
Application of Circulating Tumor DNA Test in the Diagnosis and Treatment of Patients With Advanced Rectal Cancer
Application of circulating tumor DNA detection in diagnosis and treatment of locally advanced rectal cancer. First, to explore the feasibility of ctDNA as a detection index for rectal cancer.
- Conditions
- Rectal Neoplasms, Neoadjuvant Therapy, Circulating Tumor DNA
- Trial name
- NCT03615170
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives…
- Trial name
- PROTRACT (NCT04015622)
- Testing
- Enzalutamide, Docetaxel
- Where
- 7 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Non Small Cell Lung Cancer Metastatic, Lung Diseases
PALACE: Cemiplimab Trial According to ctDNA Levels
This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB/C not candidates for definitive chemo/radiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer
- Trial name
- PALACE (NCT06917573)
- Testing
- Cemiplimab, Carboplatin, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundación GECP
Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer
Circulating Biomarkers in Oropharyngeal Cancers
The goal of this observational longitudinal study is to learn about circulating tumor Human Papilloma Virus-DNA (ctHPV-DNA) as a biomarker for HPV positive oropharyngeal cancer and cancer of unknown primary of the head and neck.
- Conditions
- Oropharynx Squamous Cell Carcinoma, Oropharynx Cancer, Tonsillar Cancer, Base of the Tongue Carcinoma
- Trial name
- CIRCOS (NCT05904327)
- Where
- Sweden
- Volunteers
- 130 people
- Sponsor
- Region Örebro County
Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases
- Trial name
- MAGNETIC1 (NCT05814224)
- Testing
- Liquid biopsy and CT scan
- Where
- 7 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
NSCLC
A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.
This is a phase II randomized study investigating whether a combination maintenance with Cemiplimab and OSE2101 (TEDOPI®) could increase ctDNA clearance rate versus standard maintenance therapy in HLA-A2 positive NSCLC patients…
- Trial name
- Cemited (NCT07264673)
- Testing
- Tedopi, Cemiplimab
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Fondazione Ricerca Traslazionale
Circulating Tumor DNA
The Value of ctDNA on Chemotherapy Efficacy for mCRC
The study is designed to evaluate the value of ctDNA in predicting the drug efficacy of chemotherapy for metastatic colorectal cancer.
- Trial name
- NCT04555369
- Testing
- ct-DNA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University
Molecular Surveillance, Breast Cancer
Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)
To learn about changes in ctDNA during the diagnosis, treatment, and post-treatment surveillance of EBC.
- Conditions
- Molecular Surveillance, Breast Cancer, ctDNA, MRD
- Trial name
- NCT07475923
- Testing
- Blood draw for the laboratory assessment, Neoadjuvant treatment
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Lung Neoplasms
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
- Conditions
- Lung Cancer, Lung Neoplasms, Cancer of Lung, Cancer of the Lung
- Trial name
- NCT02410603
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mayo Clinic